Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0242706 (
hyperoxia
)
5,219
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Exposure to
hyperoxia
results in acute lung injury. A pathogenic consequence of
hyperoxia
is endothelial injury. Macrophage migration inhibitory factor (MIF) has a cytoprotective effect on lung endothelial cells; however, the mechanism is uncertain. We postulate that the MIF receptor
CD74
mediates this protective effect. Using adult wild-type (WT), MIF-deficient (Mif(-/-)),
CD74
-deficient (Cd74(-/-)) mice and MIF receptor inhibitor treated mice, we report that MIF deficiency or inhibition of MIF receptor binding results in increased sensitivity to
hyperoxia
. Mif(-/-) and Cd74(-/-) mice demonstrated decreased median survival following
hyperoxia
compared to WT mice. Mif(-/-) mice demonstrated an increase in bronchoalveolar protein (48%) and lactate dehydrogenase (LDH) (68%) following 72 hours of
hyperoxia
. Similarly, treatment with MIF receptor antagonist resulted in a 59% and 91% increase in bronchoalveolar lavage protein and LDH, respectively. Inhibition of
CD74
in primary murine lung endothelial cells (MLECs) abrogated the protective effect of MIF, including decreased
hyperoxia
-mediated AKT phosphorylation and a 20% reduction in the antiapoptotic effect of exogenous MIF. Treatment with MIF decreased
hyperoxia
-mediated H2AX phosphorylation in a
CD74
-dependent manner. These data suggest that therapeutic manipulation of the MIF-
CD74
axis in lung endothelial cells may be a novel approach to protect against acute oxidative stress.
...
PMID:Endothelial CD74 mediates macrophage migration inhibitory factor protection in hyperoxic lung injury. 2560 32